Current and emerging therapies in Becker muscular dystrophy (BMD)

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Becker muscular dystrophy (BMD) is a genetic neuromuscular disorder characterized by progressive muscle weakness.
• It results from dystrophin gene (Xp21.2) mutations leading to dystrophin deficiency.
• BMD typically manifests in childhood, often by age 11, with variable clinical presentations.

Observation:

• Common symptoms include waddling gait, exercise-induced cramps, and myoglobinuria.
• Cardiomyopathy can rarely be the initial presenting feature.
• Phenotypic variability and slow progression are characteristic of BMD.

Findings:

• A multifactorial treatment regimen, including personalized steroid therapy, is reviewed.
• Early intervention for cardiomyopathy with ACE inhibitors is recommended.
• Multidisciplinary care, incorporating physiotherapy, is crucial for managing joint contractures and maintaining ambulation.

Implications:

• Despite childhood onset, independent walking is typically preserved into the third decade.
• Personalized medicine approaches are essential for tailoring treatment to individual BMD cases.
• Timely cardiac evaluation and management, including transplantation referral for severe cases, are vital.